[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,757,558
  • Shares Outstanding, K 160,044
  • Annual Sales, $ 276,980 K
  • Annual Income, $ -59,500 K
  • EBIT $ -45 M
  • EBITDA $ -30 M
  • 60-Month Beta 2.15
  • Price/Sales 10.04
  • Price/Cash Flow N/A
  • Price/Book 12.38

Options Overview Details

View History
  • Implied Volatility 92.06% (-15.98%)
  • Historical Volatility 74.76%
  • IV Percentile 32%
  • IV Rank 13.15%
  • IV High 260.99% on 02/17/26
  • IV Low 66.48% on 05/19/26
  • Expected Move (DTE 22) 1.23 (6.37%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 723
  • Volume Avg (30-Day) 240
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 3,049
  • Open Int (30-Day) 1,801
  • Expected Range 18.11 to 20.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 4
  • High Estimate $-0.11
  • Low Estimate $-0.15
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.66 +41.58%
on 05/26/26
19.74 -2.03%
on 06/24/26
+5.46 (+39.34%)
since 05/22/26
3-Month
12.02 +60.90%
on 03/27/26
19.74 -2.03%
on 06/24/26
+5.44 (+39.14%)
since 03/24/26
52-Week
9.96 +94.27%
on 07/31/25
20.76 -6.84%
on 11/25/25
+8.69 (+81.60%)
since 06/24/25

Most Recent Stories

More News
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase...

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system...

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to...

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference

Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted...

ADPT : 19.34 (+12.25%)
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies: Q1 Earnings Snapshot

Adaptive Biotechnologies: Q1 Earnings Snapshot

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies Reports Tomorrow With MRD Segment Under Microscope

Barchart Research What to Expect from ADPT Earnings ADPT Generated May 4, 2026 Current Price $14.50 EPS Estimate $$-0.16 Consensus Rating Strong Buy Average Move 8.43% Adaptive Biotechnologies Reports...

ADPT : 19.34 (+12.25%)
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 19.34 (+12.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 22.41
2nd Resistance Point 21.08
1st Resistance Point 20.21
Last Price 19.34
1st Support Level 18.00
2nd Support Level 16.67
3rd Support Level 15.80

See More

52-Week High 20.76
Last Price 19.34
Fibonacci 61.8% 16.63
Fibonacci 50% 15.36
Fibonacci 38.2% 14.08
52-Week Low 9.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.